BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 19778847)

  • 1. T-cell prolymphocytic leukemia.
    Dearden CE
    Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S239-43. PubMed ID: 19778847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T-cell prolymphocytic leukemia.
    Khot A; Dearden C
    Expert Rev Anticancer Ther; 2009 Mar; 9(3):365-71. PubMed ID: 19275513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study.
    Krishnan B; Else M; Tjonnfjord GE; Cazin B; Carney D; Carter J; Ketterer N; Catovsky D; Ethell M; Matutes E; Dearden CE
    Br J Haematol; 2010 Jun; 149(6):907-10. PubMed ID: 20201944
    [No Abstract]   [Full Text] [Related]  

  • 4. A case report of T cell prolymphocytic leukemia and Kaposi sarcoma and a review of T cell prolymphocytic leukemia.
    Paul RN; Alizadeh L; Ajayi OI; Karpurapu H; Ganesan C; Taddesse-Heath L; Aggarwal A
    Acta Haematol; 2012; 127(4):235-43. PubMed ID: 22517037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B- and T-cell prolymphocytic leukemia: antibody approaches.
    Dearden C
    Hematology Am Soc Hematol Educ Program; 2012; 2012():645-51. PubMed ID: 23233647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H.
    Dearden CE; Matutes E; Cazin B; Tjønnfjord GE; Parreira A; Nomdedeu B; Leoni P; Clark FJ; Radia D; Rassam SM; Roques T; Ketterer N; Brito-Babapulle V; Dyer MJ; Catovsky D
    Blood; 2001 Sep; 98(6):1721-6. PubMed ID: 11535503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T-cell prolymphocytic leukemia: update and focus on alemtuzumab (Campath-1H).
    Cao TM; Coutre SE
    Hematology; 2003 Feb; 8(1):1-6. PubMed ID: 12623420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current treatment options in prolymphocytic leukemia.
    Robak T; Robak P
    Med Sci Monit; 2007 Apr; 13(4):RA69-80. PubMed ID: 17392661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolymphocytic Leukemia: New Insights in Diagnosis and in Treatment.
    Collignon A; Wanquet A; Maitre E; Cornet E; Troussard X; Aurran-Schleinitz T
    Curr Oncol Rep; 2017 Apr; 19(4):29. PubMed ID: 28324286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of alemtuzumab in the management of T-cell malignancies.
    Dearden C
    Semin Oncol; 2006 Apr; 33(2 Suppl 5):S44-52. PubMed ID: 16720203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conjunctival involvement with T-cell prolymphocytic leukemia: report of a case and review of the literature.
    Lee SS; Robinson MR; Morris JC; Mirtsching BC; Shen D; Chan CC
    Surv Ophthalmol; 2004; 49(5):525-36. PubMed ID: 15325197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
    Hale G; Slavin S; Goldman JM; Mackinnon S; Giralt S; Waldmann H
    Bone Marrow Transplant; 2002 Dec; 30(12):797-804. PubMed ID: 12476271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunophenotypic characterization of T-cell prolymphocytic leukemia.
    Chen X; Cherian S
    Am J Clin Pathol; 2013 Nov; 140(5):727-35. PubMed ID: 24124154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complete response to alemtuzumab in a patient with B prolymphocytic leukemia.
    Chaar BT; Petruska PJ
    Am J Hematol; 2007 May; 82(5):417. PubMed ID: 17160995
    [No Abstract]   [Full Text] [Related]  

  • 15. T-cell prolymphocytic leukemia: A rare disease in an elderly female.
    Madaris L
    J Am Acad Nurse Pract; 2010 Dec; 22(12):648-53. PubMed ID: 21129072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mature T-cell leukemias.
    Ravandi F; Kantarjian H; Jones D; Dearden C; Keating M; O'Brien S
    Cancer; 2005 Nov; 104(9):1808-18. PubMed ID: 16136598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: A Single-Center Experience.
    Damlaj M; Sulai NH; Oliveira JL; Ketterling RP; Hashmi S; Witzig T; Nowakowski G; Call TG; Shanafelt TD; Ding W; Hogan WJ; Litzow MR; Patnaik MM
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):699-704. PubMed ID: 26422251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-cell large granular lymphocytic (T-LGL) leukemia: experience in a single institution over 8 years.
    Aribi A; Huh Y; Keating M; O'brien S; Ferrajoli A; Faderl S; Wierda W; Kantarjian H; Ravandi F
    Leuk Res; 2007 Jul; 31(7):939-45. PubMed ID: 17045649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolymphocytic leukemia.
    Absi A; Hsi E; Kalaycio M
    Curr Treat Options Oncol; 2005 May; 6(3):197-208. PubMed ID: 15869731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are we improving the outcome for patients with T-cell prolymphocytic leukemia by allogeneic stem cell transplantation?
    Herling M
    Eur J Haematol; 2015 Mar; 94(3):191-2. PubMed ID: 25712069
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.